Aurinia Pharm Ord (AUPH) |
|
14.6 0.97 (7.12%)
|
01-21 00:36 |
|
Open: |
13.91 |
Pre. Close: |
13.63 |
|
High:
|
14.91 |
Low:
|
13.82 |
|
Volume:
|
6,122,451 |
Market Cap:
|
1,843M |
|
|
|
|
Aurinia Pharmaceuticals Inc., a clinical stage biopharmaceutical company, develops and commercializes therapies to treat various diseases in the United States and China. It is involved in developing voclosporin, an investigational drug for the treatment of lupus nephritis, dry eye syndrome, and focal segmental glomerulosclerosis. The company is headquartered in Victoria, Canada. |
Stock Price Prediction |
Update at 5:00pm EST |
|
If tomorrow:
|
Open lower
|
Open higher
|
|
High:
|
14.929 - 14.99 |
14.99 - 15.047 |
|
Low:
|
13.678 - 13.741 |
13.741 - 13.802 |
|
Close:
|
14.494 - 14.598 |
14.598 - 14.696 |
|
Technical analysis |
as of: 2021-01-20 4:44:37 PM |
|
Overall:
|
  |
| Stoxline posted a BUY today, upgraded from lower rating. Upward movement to be expected. |
| Target: |
Six months: 18.27 One year: 21.34 |
| Support: |
Support1: 13.80 Support2: 12.65 |
| Resistance: |
Resistance1: 15.64 Resistance2: 18.27 |
| Pivot: |
13.77 |
| Moving Average: |
MA(5): 13.98 MA(20): 13.74
MA(100): 14.43 MA(250): 15.29  |
| MACD: |
MACD(12,26): -0.04 Signal(9): -0.13 |
| Stochastic oscillator: |
%K(14,3): 48.57 %D(3): 49.38 |
| RSI: |
RSI(14): 55.90 |
| 52-week: |
High: 20.48 Low: 9.83 Change(%): -23.3 |
| Average Vol(K): |
3-Month: 218543 10-Days: 408956 |
|
Price, moving averages and Bollinger Bands |
|
Price and moving averages has closed above its Short term moving average. Short term moving average is currently below mid-term; AND below long term moving averages. From the relationship between price and moving averages; we can see that: This stock is NEUTRAL in short-term; and BEARISH in mid-long term.AUPH has closed below upper band by 3.3%. Bollinger Bands are 16.7% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices. |
|
|
Headline News |
Sat, 16 Jan 2021
The Week Ahead In Biotech: FDA To Issue Decisions On Merck And Aurinia Drug Applications - Benzinga
Thu, 17 Dec 2020
Aurinia Announces Collaboration and Licensing Agreement with Otsuka Pharmaceutical Co., Ltd. for the Development and Commercialization of Voclosporin in Europe and Japan - Yahoo Finance
Fri, 13 Nov 2020
Aurinia Stock to Surge by 80%? This 5-Star Analyst Thinks It’s Possible - Nasdaq
Tue, 10 Nov 2020
Aurinia Pharmaceuticals: Q3 Earnings Insights - Yahoo Finance
Thu, 05 Nov 2020
Aurinia Pharmaceuticals (AUPH) Expected to Beat Earnings Estimates: Can the Stock Move Higher? - Yahoo Finance
Wed, 16 Sep 2020
Hedge Funds Can’t Stop Buying Aurinia Pharmaceuticals Inc (AUPH) - Yahoo Finance
|
Financial Analysis |
| Growth |
 |
| Growth measures the growth of both a company's revenue and net income. it tells investors how fast a company is growing. |
| Profitability |
 |
| Profitability measures a company’s ability to generate earnings as compared to its expenses and other relevant costs. |
| Solvency |
|
| Solvency measures a company's ability to meet its long-term debts. Acceptable solvency ratios will vary from industry to industry. |
| Efficiency |
|
| Efficiency measures the strength of a company's return on invested capital. It can identify business that are better managed or not. |
| Price to Book Value: |
Outperform |
Discounted cash flow: |
Outperform |
| Return on Assets: |
Neutral |
Price to Earnings: |
Underperform |
| Return on Equity: |
Neutral |
Debt to Equity: |
Neutral |
|
|
|
|
|
|
| Free Technical Analysis Charts
|
|
|
Stock Basics & Statistics |
| Exchange: NASDAQ |
| Sector: Healthcare |
| Industry: Biotechnology |
| Shares Out. (M) |
126 |
| Shares Float (M) |
111 |
|
% Held by Insiders
|
9.77 |
|
% Held by Institutions
|
55.87 |
|
Shares Short (K)
|
5,220 |
|
Shares Short P. Month (K)
|
5,120 |
Stock Financials |
|
EPS
|
-1.410 |
|
EPS Est This Year
|
-1.010 |
|
EPS Est Next Year
|
-0.390 |
|
Book Value (p.s.)
|
3.150 |
|
Profit Margin
|
|
|
Operating Margin
|
-93735.90 |
|
Return on Assets (ttm)
|
-22.4 |
|
Return on Equity (ttm)
|
-59.9 |
|
Qtrly Rev. Growth
|
-87.4 |
|
Gross Profit (p.s.)
|
-0.416 |
|
Sales Per Share
|
0.001 |
|
EBITDA (p.s.)
|
-0.858 |
|
Qtrly Earnings Growth
|
|
|
Operating Cash Flow (M)
|
-101 |
|
Levered Free Cash Flow (M)
|
-61 |
Stock Valuations |
|
PE Ratio
|
-10.35 |
|
PEG Ratio
|
|
|
Price to Book value
|
4.63 |
|
Price to Sales
|
15754.27 |
|
Price to Cash Flow
|
-18.32 |
Stock Dividends |
|
Dividend
|
|
|
Forward Dividend
|
|
|
Dividend Yield
|
|
|
Dividend Pay Date
|
Invalid DateTime. |
|
Ex-Dividend Date
|
Invalid DateTime. |
|
7 Binary Options
|
|
Your Ad Here
|
|
